Explore Our Publications
Entrada’s commitment to publications & transparency
Entrada is committed to publishing the results of our sponsored research in a transparent, scientifically accurate, and timely manner. Entrada will apply high ethical standards to our publications and presentations and will adhere to recognized industry guidance such as International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals and International Society for Medical Publication Professionals (ISMPP) Good Publication Practice for Communicating Company Sponsored Medical Research.
Upcoming Presentations
-
Adaptation of a Solid-Phase Peptide Synthesis Instrument for Automated Phosphorodiamidate Morpholino Oligomer (PMO) Synthesis
- By: Amanda Dombroski, PhD, Senior Scientist II, Discovery Chemistry, Entrada Therapeutics
- At: The 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
- On: October 12, 2026
October 12, 2026 -
Development of the Endosomal Escape Vehicle (EEV™) Platform for Enhanced Delivery of Oligonucleotides to Skeletal and Cardiac Muscle
- By: Mark Xiulong Shen, PhD, Associate Director, Discovery Biology, Entrada Therapeutics
- At: The 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
- On: October 12, 2026
October 12, 2026 -
Preclinical Efficacy of ENTR-601-51 for the Treatment of Exon 51 Skip–Amenable Duchenne Muscular Dystrophy
- By: Haoming Liu, PhD, Principal Scientist, Discovery Biology, Entrada Therapeutics
- At: The 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
- On: October 12, 2026
October 12, 2026 -
Preclinical Efficacy of ENTR-801 for the Treatment of USH2A-Associated Retinitis Pigmentosa Amenable to Exon 13 Skipping
- By: Pingjuan Li, MD, PhD, Director, Ophthalmology Research & Clinical Development, Entrada Therapeutics
- At: The 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
- On: October 13, 2026
October 13, 2026
Past Presentations
-
Pharmacokinetic and Pharmacodynamic Translation of ENTR-601-44, an Investigational Therapy for Patients with Exon 44 Skip-Amenable DMD
- By: Ridhi Parasrampuria, PhD, Senior Director, Clinical Pharmacology, Entrada Therapeutics
- At: 31st Annual Congress of the World Muscle Society
- On: October 2, 2026
DownloadOctober 2, 2026 -
Preclinical Efficacy of ENTR-801 for the Treatment of USH2A-Associated Retinitis Pigmentosa Amenable to Exon 13 Skipping
- By: Pingjuan Li, MD, PhD, Director, Ophthalmology Research & Clinical Development, Entrada Therapeutics
- At: XXVII Biennial Meeting of the International Society for Eye Research
- On: August 24, 2026
DownloadAugust 24, 2026 -
Preclinical Efficacy of ENTR-601-51 for the Treatment of Exon 51 Skip-Amenable Duchenne Muscular Dystrophy
- By: Christopher M. Brennan, PhD, Senior Scientist, Entrada Therapeutics
- At: 19th International Congress on Neuromuscular Diseases
- On: July 8, 2026
DownloadJuly 8, 2026 -
ENTR-601-44-201: First-in-Patient Results From a Phase 1/2 Study Evaluating ENTR-601-44 in Exon 44 Skip-Amenable DMD
- By: Laurent Servais, MD, PhD, Department of Paediatrics, MDUK Oxford Neuromuscular Centre & NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
- At: 19th International Congress on Neuromuscular Diseases
- On: July 8, 2026
DownloadJuly 8, 2026 -
Delivery of Antisense Oligonucleotides to Satellite Cells in Preclinical Models of Duchenne Muscular Dystrophy
- By: Sweta Girgenrath, PhD, Vice President, Therapeutic Research and External Innovation Lead, Entrada Therapeutics
- At: MDA Clinical & Scientific Conference
- On: March 11, 2026
DownloadMarch 11, 2026 -
Preclinical Efficacy of ENTR-601-51 for the Treatment of Exon 51 Skip-Amenable Duchenne Muscular Dystrophy
- By: Michael St. Andre, PhD, Principal Scientist, Entrada Therapeutics
- At: MDA Clinical & Scientific Conference
- On: March 10, 2026
DownloadMarch 10, 2026